About
Revagenix develops precision-engineered medicines targeting serious chronic diseases, with a lead program focused on an inhaled therapy for non-CF bronchiectasis entering Phase 1 clinical development.
Explore Revagenix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.